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ABSTRACT. During a 24-month period (May 1981 to 
May 1983), 47 pediatric patients (ranging in age from 7 
months to 18 years) underwent orthotopic liver trans-
plantation using cyclosporine and prednisone. Major in-
dications were biliary atresia/hypoplasia, and metabolic 
liver disease. Thirty-two of 138 patients evaluated for the 
procedure died prior to transplantation. Thirty patients 
are alive from 6 to 29 months later including 7/15 patients 
who required retransplantation. Twenty-one of 32 pa-
tients are alive at 1 year following initial transplantation. 
All 30 survivors are clinically well and living at home; 
only one has an -abnormal bilirubin- level. Serious, life-
threatening medical and surgical complications were 
i:ommon during' the early months following transplanta-
tion. With one exception, deaths and major rejection 
episodes occurred early (before 120 days). All survivors 
are relieved of the stigmata of chronic liver disease, and 
many have demonstrated catch-up growth. Liver trans-
plantation is an effective treatment for end-stage pedi-
atric liver disease. Pediatrics 1984;74:140-145; transplan-
tation, liver disease, biliary atresia, a-l-antitrypsin, he-
patic failure. 
After' a series of initial failures, the first success-
ful human liver transplantation took place in 1967 
in Denver. The patient, a 11/2-year-old girl with 
hepatocellular carcinoma, lived for more than 1 
year before dying from metastases. 1 Since that time, 
more than 400 transplantations have been per-
formed throughout the world.1- 7 Prior to 1980, sur-
vival at 1 year averaged 30% with an excellent long-
term outlook for those who had normal liver func-
tion at 1 year after transplantation. With the intro-
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duction of cyclosporine in the autumn of 1980,8,9 
clinical trials with this drug were initiated. 1o,11 Pre-
liminary success with a cyclosporine/steroid com-
bination led us to consider treating a larger group 
of children. From May 1981 to May 1983, 47 pa-
tients underwent orthotopic liver transplantation 
at the Children's Hospital of Pittsburgh. The re-
sults of this treatment are reported here. 
PATIENTS AND METHODS 
Patients were examined for the procedure during 
a short hospital stay (average 4 days) after referral 
from their primary physician. Preoperative evalu-
ation emphasized anatomic suitability (patency and 
size of po$! vein), confirmation of diagnosis, and 
current status (progression of hepatic disease, a 
search for other major systemic disease, associated 
vitamin and nutritional deficiencies and base-line 
assessment of growth, development, and family sit-
uation). During the 2 years, 138 patients were eval-
uated, but 18 were deemed unsuitable, mainly be-
cause of anatomic abnormalities (usually vascular), 
disease of other organ systems which precluded 
transplantation (ie, severe primary renal disease or 
severe hepatogenic cyanosis), or lack of severity of 
underlying disease. Of the remaining patients, 47 
children, ranging in age from 7 months to 18 years, 
had the pr~edureK Thirty-two children died prior 
to transplantation and 41 are currently awaiting 
grafts. Average waiting period from the time of 
evaluation to transplant was 71 days, with a range 
of 5 to 330 days. _ 
Candidates for the procedure were seiected based 
on the poor prognosis of their liver disease and 
included patients with liver failure (manifested by 
decreasing synthetic function, gastrointestinal 
bleeding, and encephalopathy12), patients with liver 
diseases that have a well-defined progressive course 
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(eg, familial cholestasisJ3.14 or biliary atresia with 
icterus post portoenterostomy16), and patients with 
severe hepatic-based metabolic diseases (eg, 0'-1-
antitrypsin deficiency with progressive liver disese 
and other metabolic disease with secondary tumors, 
such as tyrosinemiaJ6-J8). Patients with questiona-
ble indications were often followed and made can-
didates for transplantation when their disease 
showed progression despite medical intervention. 
We did not include patients with primary malignant 
tumors because of organ shortage and the high 
recurrence rate reported previously.J9.20 Matching 
was done by size and blood group, but no attempt 
was made to match human lymphocyte antigen 
(HLA) loci. With rare exceptions, the more criti-
cally ill patients were given the highest priority. 
Surgical techniques have been modified over 
many years and this has contributed substantially 
to improved outlook.7 Veno-veno bypass techniques 
were utilized in several of our patients, but this has 
not become standard in pedatric patients.21•22 The 
immunosuppression regimen included cyclosporine 
given intravenously preoperatively (5 mg/kg), then 
postoperatively 5 to 7.5 mg/kg/d divided every eight 
to 12 hours, and then orally when tolerated (average 
17.5 mg/kg/d) divided every 12 hours. An intrave-
nous burst of steroid was given for five days (usually 
st,arting at 100 mg of methylprednisolone), taPered 
and then switched to oral prednison~ at 10 to 20 
mg/d. With the increasing availability of cyclospor-
ine levels measured by high-pressure liquid 
chromatographra and the evidence of variability of 
oral absorption, a period of intravenous/oral over-
lap was initiated in 1983 to maintain adequate 
levels. We generally accepted trough blood levels 
between 150 and 500 ng/mL. In several instances, 
detailed kinetic data were obtained to allow for 
mor~ precise administration. We did not rigidly 
adhere to blood levels- in -patients who were doing 
well, as the rel~tionship between cyclosporine level 
and immunosuppression is still under investigation. 
However, in patients with transplant rejection or 
toxic .side effects, doses were raised or lowered 
according to blood level. 
Growth data included information sent from pri-
mary physicians and measurements made at the 
time of initial evaluation and follow-up in Pitts-
burgh; patients were measured supine with tape 
measure until age 3 years and then standing on a 
standard metal scale. More recent follow-up eval-
uations have included statio meter measurements. 
Rejection was characterized by rising transami-
nase' bilirubin, and canalicular enzyme levels often 
associated with fever, malaise, and hepatomegaly. 
Attempts were made to eliminate other conditions 
such as obstruction or ischemia, but occasional 
overlap did.'occur. Rejection episodes were variable 
in severity, and several features could be missing 
or prominent in an individual patient.6•7 Standard 
treatment included intravenous steroid boluses in 
high doses usually with a five-day increase and 
tapering of oral prednisone (recycle). Liver biopsy 
was reserved for patients who did not respond 
quickly to antirejection therapy or for those with a 
high suspicion of other disorders (eg, viral infection 
or cholangitis). Pathologic changes are currently 
under study, but the features most consistently seen 
in children who responded to antirejection therapy 
were (1) lymphocyte infiltration of the portal areas, 
(2) hepatocyte necrosis at the limiting plate, and 
(3) epithelial damage to small bile ducts. 
Patients are referred to by orthotopi~ transplant 
(OT) number based on sequential procedures in the 
Denver-Pittsburgh series in order to make identi-
fication easier in subsequent publications. The sur-
vival curve was derived by using standard methods 
of life table analysis.24 Patients are considered as a 
group undergoing transplantation and are not with-
drawn when retransplantation is required. 
RESULTS 
Indications, Operations, and Current Status 
The indications for transplantation are suinma-
rized in Table 1: Extrahepatic -biliary atresia and 
biliary hypoplasia (paucity of intrahepatic bile 
ducts) accounted for nearly half of the 47 patients 
(22 patients). The other large group included 13 
children wit~ metabolic disorders; there were eight 
with a-I-antitrypsin deficiency (and two deaths), 
two with Wilson's disease (one death), and one 
each with type 1 glycogen storage disease, heredi-
tary tyrosinemia/hepatoma, and sea-blue histio-
cyte/hepatoma syndrome, respectively (no deaths). 
During the study period, nearly one third of the 
47 patients required repeat transplantation; 13 pa-
tients received two grafts and two received three 
grafts for a total of 64 grafts. Eleven of the initial 
retransplantation procedures were done within the 
TABLE 1. Indications for Transplantation 
Biliary atresia 
Biliary hypoplasia 
Metabolic diseases 
Familial cholestasis 
Chronic active hepatitis 
Choledochal cyst/cirrhosis 
Neonatal hepatitis 
Benign liver tumor 
Total 
No. of No. of 
Patients Deaths 
19 
3 
13 
5 
4 
1 
1 
1 
47 
7 
2 
3 
2 
2 
1 
17 
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first postoperative month; the others were scattered 
up to 244 days later. Third grafts were done at 61 
and 291 days. Graft survival is as follows: 23/47 
first grafts (49%),6/15 second grafts (40%), and 1/ 
2 third grafts (50%). The current survival rate for 
those with repeat transplantation is 47% (7/15), in 
contrast to the overall rate of 64%. 
Thirty of the 47 patients are currently surviving 
6 to 29 months after surgery with an average follow-
up period of 12 months. Twenty-one of 32 patients 
are well 1 year after initial transplantation. Current 
status of graft function for the 30 surviving patients 
is excellent for 28 (bilirubin, 0.2 to 1.1 mg/dL; 
SGPT, 12 to 100 IU/mL) and good for two (biliru-
bin, 0.7 to 2.6 mg/dL; SGPT, 79 to 170 IU/mL). 
All patients are living at home, and all are clinically 
well. One child has resolving, mild chronic rejec-
tion, which occurred after immunosuppression was 
reduced following development of a small-bowel 
lymphoproliferative disorder associated with an in-
crease in antibodies to the Epstein-Barr virus.26•26 
There is no sign of tumor 10 months later. Another 
child has developed mild, biopsy-proven rejection 
recently as cyclosporine dose was reduced, although 
her bilirubin level remains normal. 
Immunosuppressive medication averaged 15 mg/ 
kg/d of cyclosporine and 0.3 mg/kg/d of prednisone 
in the 30 survivors. By 1 year after transplantation, 
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daily doses of cyclosporine averaged 11 mg/kg and 
Iprednisone 5 mg/d. 
Deaths 
A survival curve for the entire group is shown in 
the Figure. Most deaths occurred within 1 month 
and all except one occurred within 120 days of the 
initial operation. There were no deaths during sur-
gery; four deaths occurred in the week following 
initial surgery, five deaths in the second, and one 
death each in the third and fourth weeks and first 
and second postoperative months. Three patients 
died in the third month, and one died at 9'/2 months 
after surgery. Deaths were multifactorial, and in 
many cases it was impossible to choose a single 
cause. Infection often supervened in cases of 
chronic rejection or vascular occlusion. We have 
listed primary and secondary causes of death in 
Table 2. Three patients died due to complications 
of transplant rejection and one (patient OT 214) 
had a segmental portal vein occlusion as well. In-
fections were terII}inal events in all three patients. 
Preexisting portal vein thrombosis (OT 220) and 
absent superior vena cava (OT 233) precluded sur-
vival in two patients, and major postoperative vas-
cular occlusions (one portal vein lOT 259) and one 
hepatic artery lOT 267» were lethal in two others. 
In twq children, death was caused by bacterial 
(21) (12) (7) 
12 11 
Time(months) 
Figure. Survival rate following liver transplantation. Values in parentheses represent 
patients followed for time indicated. 
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TABLE 2. Primary and Secondary Factors in 17 Deaths 
Primary Secondary 
Rejection 
Vascular anomalies. preoperative 
Vascular complications (surgical) 
Infection 
Massive liver infarction (early) 
with patent vessels (late) 
Cerebrovascular accident/edema 
3 2 
2 1 
2 1 
3 4 
3 
2 
2 
sepsis (OT 201 and OT 228). but problems with 
biliary anastomosis may have contributed to ab-
scess and sepsis in one of these. One patient died 
of complications of cytomegalovirus pneumonia 
More difficult to explain are the deaths of five 
patients with massive hepatic necrosis and patent 
vascular anastomoses. Three deaths (OT 265, OT 
271, and OT 279) occurred just after transplanta-
tion and may have represented defective organs. 
The other deaths (OT 232 and OT 240) occurred 
approximately 11 days later and may have been 
related to rejection-induced ischemia. One of these 
later events may be related to preexisting vascular 
anomalies and poor blood flow (absent inferior vena 
cava, preduodenal portal vein, and abnormal he-
patic artery takeoff).27 The primary cause of death 
in two patients was a CNS catastrophe. A massive 
cerebrovascular accident in one patient (OT 203) 
followed a third transplantation; irreversible hepa-
togenic cyanosis may have contributed to this 
event. The other patient (OT 284) had acute cere-
bral edema while undergoing dialysis after success-
ful retransplantation. 
Complications in Survivors 
Complications in the 30 survivors were multiple 
as could be suspected from the average hospital 
stay of 54 days. Because minor complications oc-
curred frequently, we-chose to look at major, life-
threatening ~mes with onset occurring either before 
2 months (early) or after 2 month~ (late) and usu-
ally following discharge from the hospital. This 
demarcation was chosen because most survivors 
were discharged and clinically well at 2 months 
after transplantation. 
Early Complicatiom. Early hypertension was al-
most uniform, but transient, in 29/30 survivors 
allowing discontinuation of therapy by 3 months 
after surgery. Hypertension remains unexplained 
but was also seen in the precyclosporine era.6 Five 
patients had hypertensive seizures despite institu-
tion of therapy. Oral captopril was useful in difficult 
cases. Rejection episodes (21/30 patients) fre-
quently occurred early and usually responded to 
increased immunosuppression. Serious, life-threat-
ening infections occurred in eight patients. Most 
episodes were viral: herpes virus (one patient), ad-
enovirus (two patients), and cytomegalovirus (two 
patients). There were also two major fungal (Can-
dida sp) and four major bacterial infections, along 
with numerous local wound infections. Biliary tract 
complications occurred in 5/30 patients; these re-
quired drainage after leakage in three patients and 
early revision of the anastomosis in two. Prolonged 
tracheostomy (more than 1 month) was required in 
four patients. Vascular thrombosis (requiring re-
transplantation) occurred in three patients. Two 
patients had insulin-dependent, but transient, dia-
betes mellitus, presumably from steroid therapy. 
Late Complicatiom. Episodes of rejection were 
less frequent and generally less severe after 2 
months, but did occur in seven patients. These 
episodes were easily controlled with adjustments in 
immunosuppressive therapy. Complete portal vein 
occlusion with bleeding esophageal varices occurred 
in two patients, both of whom had previous porto-
caval shunts. Remarkl\bly, both patients demon-
strated hepatopedal flow to the grafted liver 
through new collaterals, and both maintained nor-
mal liver function. One patient underwent success-
ful distal splenorenal shunt (Warren procedure) for 
recurrent bleeding despite sclerotherapy, and the 
other patient's condition is stable after sclerother-
apy. Two patienti developed splenomegaly and hy-
persplenism from poltaI vein stricture with suc-
cessful revision in one patient, and slow, a~ympto­
matic improvement in the other. Biliary tract stric-
ture with obstruction developed late in two patients. 
It was successfully treated in one patient, ana the 
other developed hepatic abscess following surgery 
but eventually underwent successful -retransplan-
tation. Later in recovery, two patients developed 
hypertension related to steroid and cyclosporine 
toxicity. Pneumocystis carinii pneumonia was doc-
umented by open lung biopsy in one child and 
presumed in another because there was an appro-
priate response to trimethoprim/sulfamethoxazole. 
One patient developed pseudotumor cerebri with 
unilateral visual impairment, possibly related to 
steroid reduction. Pressure has returned to normal 
after lumboperitoneal shunt. The patient with sea-
blue histiocyte syndrome with progressive neuro-
logic deterioration and a small hepatoma is now in 
stabilized condition with improved ambulation, but 
there are storage cells in the transplanted liver.28 
One patient developed a lymphoproliferative dis-
order. 
Growth, Development, and Quality of Life 
Growth data are available in 24 patients with 
follow-up of at least 6 months. Two patients in the 
series are fully grown"adolescents and have re-
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mained the same height. Of the others, 11/22 have 
demonstrated catch-up growth, crossing percentile 
lines. All but one of the other 11 patients have 
maintained a normal growth rate at the preopera-
tive percentile, although several have growth rates 
below and parallel to the fifth percentile. The child 
with the sea-blue histiocyte syndrome who was 
treated for presumed rejection with high-dose ste-
roid for several months and whose repeat liver 
biopsy showed recurrent storage cells has had 
growth deceleration. 
All 30 children are living at home with previous 
caretakers; psychological and developmental fol-
low-up information is being obtained. Pruritus, 
xanthomata, icterus, organomegaly, clubbing, and 
malnutrition have improved or disappeared. Nearly 
all patients have had increased energy, and school-
aged children have returned to regular classes. 
However, the stress of recurrent esophageal varices 
and worry about retransplantation have produced 
anxiety and depression in several of our patients. 
Older children, in general, have had more anxiety 
about the future, and several fear rejection of the 
graft. 
DISCUSSION 
The previous high operative mortality and com-
plex nature of liver transplantation made it a r~e 
procedure, especially in the pediatric age group. 
'Eighty-six pediatric patients received grafts in Den-
ver, by far the major series, from 1963 to 1979 in 
the precyclosporine era with a current survival rate 
of 21 % overal1.7 The average survival in the latter 
part of the series was 30% overall. The 64 % survival 
figure in our current series may appear overly op-
timistic as all patients are not yet 1 year posttrans-
plant. However, only one patient in the series with 
excellent graft function at 3 months has shown 
subsequent major rejection; this was the patient 
with a lymphoproliferative disorder whose immu-
nosuppression therapy had to be reduced. Barring 
unforeseen new disorders, most of these patients 
should be long-term survivors. Additional benefits 
to these children are freedom from chronic disease 
and a good chance for improved growth. 
Although liver transplantation may be used for 
the treatment of a variety of hepatic diseases, met-
abolicdisorders probably represent the best indi-
cations. The operation is often technically easier 
because of the absence of previous surgery. More 
important, there is a potential for cure ofthe met-
abolic defect as well as the secondary hepatic dis-
ease. For example, a-I-antitrypsin levels and Pi 
type normalize, suggesting that pulmonary disease 
will no longer be of concern in this condition. Poor 
quality of life and severe dietary restriction may be 
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reversed in glycogen storage disesae and tyrosine-
mia. 
A striking finding of this series is the efficacy of 
repeat transplantation. The current survival rate of 
47% for retransplantation is even better than the 
best overall results from the precyclosporine era. 
One of our patients is living and well with his third 
graft. 
The price of liver transplantation is a high one 
for most children. The procedure and postoperative 
course are characterized by numerous potential life-
threatening complications requiring constant vigi-
lance. The average hospital stay is 54 days (range 
16 to 134 days). Children and families are stressed 
constantly, as to some extent is the medical staff. 
From the onset, we were concerned about develop-
mental issues in these children. Experience in renal 
transplant programs indicated that while excellent 
graft function was generally associated with good 
psychological health, emotional difficulties oc-
curred frequently.29,30 In contrast to previous stud-
ies of liver transplant recipients',31,32 we attempted 
to obtain assessments of emotional and develop-
mental status on all patients, even those without 
overt problems. Generally, patients with excellent 
graft function have improved growth and develop-
ment, but they may need ongoing emotional sup-
port. An intensive team effort is absolutely neces-
sary for success, a team that includes nursing, social 
aervice, psychiatry, psychology, occupational and 
play therapy, and others who are aware of the 
special problems and needs of patients who have 
received transplants. We believe that with this type 
of approach, liver transplantation truly represents 
a major advance in the treatment of pediatric liver 
disease; it brings together the major advances in 
. surgery, immunology, and pediatric care of the last 
two decades. 
ADDENDUM 
Our experience with 17 additional patients from May 
1983 through October 1983 (with at least a 6-month 
follow-up) justifies continued optimism: All but two have 
been discharged and are living at home. One patient is 
still recovering in the hospital; one patient died. Five 
patients have required retransplantation thus far;'one of 
these was the child who died. 
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